Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rilpivirine Label Highlights Risk In Patients With Higher HIV Levels, Could Limit Use

This article was originally published in The Pink Sheet Daily

Executive Summary

Lead investigator from Phase III trials says Edurant could be viable option in about half of treatment-naïve patients, points out safety advantages.
Advertisement

Related Content

Gilead Complera Launch Imminent Following FDA Approval
Gilead Complera Launch Imminent Following FDA Approval
Gilead's Quad Poised To Take Chunk Of Atripla's Market, If Phase III Results Hold Up
Tibotec Files Once-Daily NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV
Tibotec Files Once-Daily NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV

Topics

Advertisement
UsernamePublicRestriction

Register

PS072270

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel